A clinical trial of an investigational RSV vaccine for adults who have received a kidney, liver, or lung transplant

The RSVoice Trial is a Phase 3 clinical trial conducted by Moderna to evaluate the safety and immune response of an investigational vaccine aimed at preventing respiratory syncytial virus (RSV) infection in adults who have received a kidney, liver, or lung transplant.

Trial Details

The purpose of this clinical trial is to evaluate the safety and immune response of 2 doses of an investigational vaccine aimed at preventing RSV infection in adults who have a weakened immune system due to having an organ transplant. An investigational vaccine is not yet approved by a country’s drug regulatory agency. All participants in the RSVoice Trial will receive the investigational vaccine. RSV is a common respiratory virus that infects the lungs and breathing passages. People most frequently associate RSV with the risk it brings to young children, but many do not know the high risk it poses for adults with preexisting health conditions and older adults. People with weakened immune systems, such as those taking immunosuppressants after an organ transplant, have a higher risk of life-threatening symptoms when infected with RSV.

Estimated Enrollment

150 Participants

Phase

3

Eligibility Criteria

 Participants must:

  • Be 18 years of age or older
  • Be a recipient of a kidney, liver, or lung transplant at least 6 months prior and be currently receiving chronic immunosuppressive therapy
 
 

 Participants must not:

  • Be pregnant or planning on becoming pregnant for at least 3 months following the final vaccine visit